The purpose of this study is to demonstrate that Visudyne therapy in patients who have occult
with no classic subfoveal choroidal neovascularization (CNV) lesions will, with an acceptable
safety profile, significantly reduce the risk of vision loss compared with placebo (sham
treatment).